Jena, Germany– ZEISS Medical Technology has announced regulatory approval from China’s National Medical Products Administration (NMPA) for its CLARUS® 700 ultra-widefield imaging system, expanding access to high-resolution retinal diagnostics for eye care professionals across the country.
The CLARUS 700 is designed to capture ultra-widefield, high-definition True Color images of the retina, including advanced capabilities for fluorescein angiography. By enabling precise imaging from the central macula to the far retinal periphery, the system supports earlier and more accurate detection of a wide range of retinal diseases.
“CLARUS 700 represents a major step forward in retinal imaging,” said Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. “By combining ultra-widefield fluorescein angiography with true-color reproduction, it enhances clinical decision-making and streamlines the ZEISS Retina Workflow.”
Now available to Chinese ophthalmologists, the CLARUS 700 offers a field of view up to 133 degrees in a single capture and up to 267 degrees through multiple captures. The system also includes features like PrecisionFocus for improved detail targeting, AutoBright for automated image optimization, and QuickCompare to assess progression across patient visits.
Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China, noted the system’s significance: “The CLARUS 700 redefines fundus angiography by offering AI-enhanced capture, unmatched diagnostic clarity, and increased patient comfort—raising the standard for eye care in China.”
The approval marks a significant expansion of ZEISS’s footprint in the Chinese ophthalmology market, offering clinicians advanced diagnostic tools to help preserve vision and improve patient outcomes.
